Title : Contribution of anti-phosphatidylserine antibodies in the diagnosis of antiphospholipid syndrome
Abstract:
Antiphospholipid syndrome is an autoimmune disease characterized by vascular thrombosis, obstetric complications, and the presence of antiphospholipid antibodies (aPL). However, diagnosis may be particularly challenging in certain patients who are seronegative for conventional antibodies. In this context, our study evaluated the diagnostic value of detecting anti-phosphatidylserine (anti-PS) IgG and IgM antibodies, as well as their clinical correlations.
Anti-PS antibodies were investigated by indirect ELISA in 482 patients referred for an aPL assessment at the autoimmunity laboratory of the Pasteur Institute. Among them, 12% showed positive aPL results, including 4% with isolated positivity for anti-PS antibodies. While anti-PS IgM antibodies showed no association with any specific clinical manifestation, anti-PS IgG antibodies were more strongly correlated with venous thrombosis and pulmonary embolism. These findings highlight the potential value of anti-PS antibodies as additional biomarkers in APS, particularly in seronegative cases, and suggest their possible contribution to improving diagnostic strategies.
Based on the abstract, some added value has been brought through our study :
- Evaluation of new biomarkers (diagnostic value and clinical correlations of anti-PS IgG and IgM antibodies.
- Adressing seronegative cases where it highlights the potential value of anti-PS as additional biomarkers in patients who test seronegative for conventional antibodies.
- The gain is insights into utilizing anti-PS which showed a stronger correlation with venous thrombosis and pulmonary embolism to better assess patients by providing a pathway to identify APS patients who might otherwise be missed by standard diagnostic testing.
- Improving diagnostic strategies : findings suggest a potential contribution to enhancing current diagnostic protocols for APS.
- Future research and clinical application: it paves the way for further validation and broader use of anti-PS antibodies to optimize patient management and diagnostic accuracy (specially IgG markers linked to venous thrombosis and pulmonary embolism.
